Beta Pharma Inc. has disclosed antibody-drug conjugates consisting of humanized monoclonal antibody trastuzumab targeting receptor tyrosine-protein kinase erbB-2 (erbB2; HER2) covalently linked to cytotoxic drug through a cleavable linker reported to be useful for the treatment of cancer.
CAR T-cell therapy has been highly effective in hematologic cancers but faces challenges in solid tumors due to the lack of safe, uniformly expressed surface antigens. A recent study found that the MiT/TFE-family fusion-driven glycoprotein NMB (GPNMB) is highly, homogeneously and stably expressed in primary and relapsed alveolar soft-part sarcoma (ASPS) and translocation renal cell carcinoma (tRCC).
Iksuda Therapeutics Ltd. has obtained IND clearance from the FDA for IKS-04, enabling initiation of a phase I trial in patients with gastrointestinal cancers.
Researchers from Jacobio Pharmaceuticals Co. Ltd. recently presented preclinical data on JAB-BX600, an EGFR-directed antibody-drug conjugate (ADC) that selectively delivers a KRAS G12D inhibitor to tumor cells, allowing dual inhibition of the EGFR-KRAS pathway.
Fortvita Biologics Inc. and Innovent Biologics (Hangzhou) Co. Ltd. have patented bispecific antibody-drug conjugates (ADCs) comprising a bispecific humanized monoclonal antibody targeting EGFR and hepatocyte growth factor receptors (HGFR; MET) linked to cytotoxic drugs reported to be useful for the treatment of cancer.
Veraxa Biotech AG has reported the advancement of its bispecific antibody-drug conjugate (bsADC) program VXA-222, following achievement of a technical milestone in its alliance with Omniab Inc. The program is moving into its next collaboration phase.
Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. said its IND application was approved in China for SKB-565, its dual-payload antibody-drug conjugate (ADC), for the treatment of advanced solid tumors.
Bioray Pharmaceutical Co. Ltd. has prepared and tested new antibody-drug conjugates consisting of antibodies covalently linked to payloads. They are reported to be potentially useful for the treatment of cancer, infections, inflammatory and immunological disorders.
Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have divulged new antibody-drug conjugates comprising antibodies targeting carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5; CEA; CD66e) covalently linked to a cytotoxic drug potentially useful for the treatment of colorectal cancer.
HCW Biologics Inc. has requested a type B (pre-IND) meeting with the FDA to discuss the development and regulatory strategy for its investigational tetravalent T-cell engager (TCE), HCW-11-018b, for solid tumors.
RSS
